PD-L1 is Fascinating but IDO Needs Attention in Non-HCV and Non-HBV-Associated Hepatocellular Carcinoma Patients

BACKGROUND/AIM: Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer that is modulated by the immune system. Programmed cell death ligand-1 (PD-L1) has emerged as a novel therapeutic target in various cancers. Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme...

Descripción completa

Detalles Bibliográficos
Autores principales: Asghar, Kashif, Bashir, Shaarif, Ali Rana, Iftikhar, Abu Bakar, Muhammad, Farooq, Asim, Hassan, Muhammad, Asif, Zukhruf, Afzal, Mahnoor, Masood, Iqra, Ishaq, Muhammad, Tahseen, Muhammad, Bilal, Sundus, Mehmood, Shafqat, Kanwal, Nosheen, Ud Din, Islah, Loya, Asif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284167/
https://www.ncbi.nlm.nih.gov/pubmed/37350801
http://dx.doi.org/10.2147/JHC.S409741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284167/
https://www.ncbi.nlm.nih.gov/pubmed/37350801
http://dx.doi.org/10.2147/JHC.S409741

Ejemplares similares